This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Apricus Biosciences Announces Formation Of Clinical Advisory Board As Part Of Its Plans To Further The Clinical Development Of Femprox(R)

Dr. Jed Kaminetsky, M.D. is a Clinical Associate Professor at New York University Medical Center and is a practicing urologist with University Urology Associates, one of the largest urologic practices in the New York City metropolitan area. He is a reputable urologist and is highly skilled in treating all urologic disorders and performing minimally invasive prostate surgeries. Dr. Kaminetsky's academic interests include the study of both male and female sexual dysfunction, which has led him to become a national and world thought leader. Dr. Kaminetsky's work has been published in several journals which led to a nationwide recognition and development of various treatment schemes for patients with sexual and erectile dysfunction, including the creation of Dream Cream, a topical formulation for the treatment of female sexual dysfunction. Moreover, Dr. Kaminetsky is an experienced principal investigator who participates in national research studies that explore pharmacologic and diagnostic techniques for various urologic disorders. He is currently conducting studies addressing premature ejaculation, ED, male and female sexual dysfunction, UTIs, BPH, acute pyelonephritis, chronic non-bacterial prostatitis, prostate cancer, voiding dysfunction, treatment and prevention of stone disease, and hypergonadism. His hospital appointments include New York University Medical Center, New York Downtown Medical Center, Saint Vincent's Hospital, and Saint Vincent's Catholic Medical Center. Dr. Kaminetsky has been consulting for several pharmaceutical companies including Bayer Corporation, UNIMED Pharmaceuticals, Pharmacia Corporation, Schering-Plough and Vivus, Inc.

Dr. Ajay Nehra, M.D. is a Professor of Urology at the Mayo Medical School, and a consultant in the Department of Urology of the Mayo Clinic, both in Rochester, MN. He received his medical degree from the All India Institute of Medical Sciences in New Delhi, and served his residency at the Boston University School of Medicine, and a residency and chief residency at Maimonides Medical Center in Brooklyn, N.Y. Dr. Nehra has been the principal investigator with more than seven clinical multicenter investigational studies of the efficacy and safety of a number of treatments for erectile dysfunction. He is a co-investigator in the National Institutes of Health program project on aging. Dr. Nehra has contributed more than 100 articles and 120 abstracts, mainly on male sexual dysfunction, male infertility, neuro-urology, prosthetics, urologic oncology and BPH. He has also written ED-related chapters of books and he has co-authored a book of commentary on sexual dysfunction in medicine. Dr. Nehra is a former President of the Sexual Medicine Society of North America, a board member of the American Urological Association and many national and international professional societies. Dr Nehra is a thought leader and consultant for many pharmaceutical companies including, GlaxoSmithKline, Pfizer, and Sanofi-Aventis.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs